Krebs Biochemicals & Industries Limited (NSE:KREBSBIO)
India · Delayed Price · Currency is INR | Market Cap | 1.23B -27.2% |
| Revenue (ttm) | 252.34M -29.7% |
| Net Income | -140.94M |
| EPS | -6.53 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,522 |
| Open | 57.54 |
| Previous Close | 57.54 |
| Day's Range | 55.51 - 57.89 |
| 52-Week Range | 38.33 - 80.00 |
| Beta | 0.87 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 6, 2026 |
About NSE:KREBSBIO
Krebs Biochemicals & Industries Limited engages in the manufacture of active pharmaceutical ingredients in India. It offers androstenedione for steroid intermediate indications, as well as lovastatin and simvastatin for anti-cholesterol applications. The company also develops amlodipine and telmisartan for anti-hypertension; cetirizine for antihistamine; orlistat for anti-obesity; serratiopeptidase for anti-inflammatory; and phenylephrine for cold and cough. In addition, it provides contract manufacturing services for large pharmaceutical and m... [Read more]
Financial Performance
In fiscal year 2026, NSE:KREBSBIO's revenue was 237.32 million, a decrease of -45.21% compared to the previous year's 433.12 million. Losses were -169.33 million, -37.14% less than in 2025.
Financial StatementsNews
Krebs Biochemicals & Industries halts production following order from Andhra Pradesh Pollution Control Board
Krebs Biochemicals & Industries Limited announced that it has been directed to immediately cease all production activities at its manufacturing unit located in Kothapalli (V), Kasimkota (M), Anakapall...